Premature physeal closure following 13-cis-retinoic acid and prolonged fenretinide administration in neuroblastoma. 2016

Angela Steineck, and John D MacKenzie, and Clare J Twist
Department of Pediatrics, Stanford University School of Medicine, Stanford, California. asteine@stanford.edu.

Retinoid therapy has contributed to improved outcomes in neuroblastoma. Clinical trials of fenretinide report favorable toxicity and disease stabilization in patients with high risk (HR) neuroblastoma. Skeletal effects have been described with other retinoids, but not with fenretinide to date. Two patients with HR, metastatic, refractory neuroblastoma received protracted courses of oral fenretinide for more than 5 years' duration. Both developed premature long bone physeal closure, causing limb length discrepancies; their neuroblastoma remains in remission. The radiographic and clinical findings reported suggest these skeletal abnormalities may be a consequence of treatment with 13-cis-retinoic acid (13cisRA) followed by prolonged oral fenretinide exposure.

UI MeSH Term Description Entries
D008297 Male Males
D009447 Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) Neuroblastomas
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006132 Growth Plate The area between the EPIPHYSIS and the DIAPHYSIS within which bone growth occurs. Cartilage, Epiphyseal,Epiphyseal Cartilage,Epiphyseal Plate,Cartilages, Epiphyseal,Epiphyseal Cartilages,Epiphyseal Plates,Growth Plates,Plate, Epiphyseal,Plate, Growth,Plates, Epiphyseal,Plates, Growth
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015474 Isotretinoin A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects. 13-cis-Retinoic Acid,Accutane,Isotretinoin Zinc Salt, 13-cis-Isomer,Ro 4-3780,Roaccutane,13 cis Retinoic Acid,Isotretinoin Zinc Salt, 13 cis Isomer,Ro 4 3780,Ro 43780
D017313 Fenretinide A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent. 4-HPR,4-Hydroxyphenylretinamide,Fenretinide, 13-cis-Isomer,Fenretinimide,MCN-R-1967,N-(4-Hydroxyphenyl)-trans-Retinamide,N-(4-Hydroxyphenyl)retinamide,13-cis-Isomer Fenretinide,4 Hydroxyphenylretinamide,Fenretinide, 13 cis Isomer,MCN R 1967,MCNR1967

Related Publications

Angela Steineck, and John D MacKenzie, and Clare J Twist
November 1982, Journal of the American Academy of Dermatology,
Angela Steineck, and John D MacKenzie, and Clare J Twist
October 2021, Journal of pediatric orthopedics,
Angela Steineck, and John D MacKenzie, and Clare J Twist
January 1985, Journal of neuro-oncology,
Angela Steineck, and John D MacKenzie, and Clare J Twist
February 2000, Drug metabolism and disposition: the biological fate of chemicals,
Angela Steineck, and John D MacKenzie, and Clare J Twist
April 1999, Medical and pediatric oncology,
Angela Steineck, and John D MacKenzie, and Clare J Twist
September 2012, Pediatric blood & cancer,
Angela Steineck, and John D MacKenzie, and Clare J Twist
January 2009, The Turkish journal of pediatrics,
Angela Steineck, and John D MacKenzie, and Clare J Twist
January 2001, Medical and pediatric oncology,
Angela Steineck, and John D MacKenzie, and Clare J Twist
May 2023, Pediatric blood & cancer,
Copied contents to your clipboard!